NAV

Aminophylline

Identification

Summary

Aminophylline is a bronchodilator consisting of theophylline that is used for the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.

Generic Name
Aminophylline
DrugBank Accession Number
DB01223
Background

Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.

Type
Small Molecule
Groups
Approved
Structure
Similar Structures
Weight
Average: 420.4264
Monoisotopic: 420.198199306
Chemical Formula
C16H24N10O4
Synonyms
  • Aminofilina
  • Aminophyllin
  • Aminophylline
  • Aminophyllinum
  • Theophyline ethylenediamine
  • Theophylline ethylenediamine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Adjunct therapy in treatment ofAcute exacerbation of chronic bronchitis••••••••••••
Management ofAsthma••••••••••••
Management ofBronchial asthma•••••••••••••••••••••••
Management ofBronchospasm•••••••••••••••••••••••
Management ofChronic bronchitis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Aminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion.

Mechanism of action

Aminophylline is the ethylenediamine salt of theophylline. After ingestion, theophylline is released from aminophylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.

TargetActionsOrganism
AcGMP-inhibited 3',5'-cyclic phosphodiesterase A
inhibitor
Humans
AAdenosine receptor A1
antagonist
Humans
AAdenosine receptor A3
antagonist
Humans
AHistone deacetylase 2
activator
Humans
Absorption

Not Available

Volume of distribution
  • 0.3 to 0.7 L/kg
Protein binding

60%

Metabolism
Not Available
Route of elimination

Not Available

Half-life

7-9 hours

Clearance
  • 0.29 mL/kg/min [postnatal age 3-15 days]
  • 0.64 mL/kg/min [postnatal age 25-57 days]
  • 1.7 mL/kg/min [ 1-4 years]
  • 1.6 mL/kg/min [4-12 years]
  • 0.9 mL/kg/min [13-15 years]
  • 1.4 mL/kg/min [16-17 years]
  • 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics]
  • 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function]
  • 0.33 mL/kg/min [Acute pulmonary edema]
  • 0.54 mL/kg/min [COPD->60 years, stable non-smoker >1 year]
  • 0.48 mL/kg/min [COPD with cor pulmonale]
  • 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
  • 0.31 mL/kg/min [Liver disease -cholestasis]
  • 0.35 mL/kg/min [cirrhosis]
  • 0.65 mL/kg/min [acute hepatitis]
  • 0.47 mL/kg/min [Sepsis with multi-organ failure]
  • 0.38 mL/kg/min [hypothyroid]
  • 0.8 mL/kg/min [hyperthyroid]
Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Aminophylline.
AbametapirThe serum concentration of Aminophylline can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Aminophylline can be increased when combined with Abatacept.
AbirateroneThe serum concentration of Aminophylline can be increased when it is combined with Abiraterone.
AcalabrutinibThe metabolism of Aminophylline can be decreased when combined with Acalabrutinib.
Food Interactions
  • Administer vitamin supplements. Aminophylline may reduce Vitamin B6 levels as an adverse effect. Consider supplementation.
  • Avoid excessive or chronic alcohol consumption. Ingesting a large amount of alcohol may reduce aminophylline clearance, therefore increasing its serum concentration.
  • Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of aminophylline.
  • Exercise caution with St. John's Wort. This herb induces the CYP3A4 metabolism of aminophylline. Therefore it may reduce the serum concentration and effectiveness of aminophylline.
  • Limit caffeine intake. Excessive caffeine intake with aminophylline may exacerbate caffiene-like side effects such as nausea, nervousness, irritability, insomnia and tremors.
  • Take with food. This may reduce gastric irritation. Aminophylline absorption is slower when taken with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Aminophylline dihydrateC229N9DX945897-66-5FXNJPZOEDHBGEY-UHFFFAOYSA-N
Active Moieties
NameKindUNIICASInChI Key
Theophyllineunknown0I55128JYK58-55-9ZFXYFBGIUFBOJW-UHFFFAOYSA-N
International/Other Brands
Minomal / Somophyllin
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AminophyllineInjection, solution25 mg/1mLIntravenousHospira, Inc.2006-11-072006-11-07US flag
AminophyllineInjection, solution25 mg/1mLIntravenousHospira, Inc.2006-11-072006-11-07US flag
Aminophylline Inj 25mg/mlSolution25 mg / mLIntravenousOmega Laboratories Ltd1984-12-31Not applicableCanada flag
Aminophylline Inj 50mg/mlSolution50 mg / mLIntravenousOmega Laboratories Ltd1984-12-31Not applicableCanada flag
Aminophylline Injection 50mg/mlSolution50 mg / mLIntravenousHospira Healthcare Ulc1981-12-312012-08-03Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AminophyllineSolution105 mg/5mLOralActavis Pharma Company2001-01-282007-03-31US flag
AminophyllineInjection, solution25 mg/1mLIntravenousGeneral Injectables & Vaccines2010-07-012011-02-01US flag
AminophyllineInjection, solution25 mg/1mLIntravenousHenry Schein, Inc.2022-01-08Not applicableUS flag
AminophyllineInjection, solution25 mg/1mLIntravenousCardinal Health2011-02-112018-09-30US flag
AminophyllineInjection, solution25 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2019-02-10Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AMINOCARDOL 10 ML 240 MG 100 AMPULAminophylline (240 mg/10ml)Injection, solutionIntravenousNOVARTİS ÜRÜNLERİ2018-07-312022-04-11Turkey flag
AMINOCARDOL 240MG/10 ML 3 AMPULAminophylline (240 mg/10ml)Injection, solutionIntravenousNOVARTİS ÜRÜNLERİ2018-07-312022-04-11Turkey flag

Categories

ATC Codes
R03DA55 — Aminophylline, combinationsR03DA05 — AminophyllineR03DA20 — Combinations of xanthinesR03DB05 — Aminophylline and adrenergics
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Monoalkylamines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aromatic heteropolycyclic compound / Hydrocarbon derivative / Organopnictogen compound / Primary aliphatic amine
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
27Y3KJK423
CAS number
317-34-0
InChI Key
FQPFAHBPWDRTLU-UHFFFAOYSA-N
InChI
InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
IUPAC Name
bis(1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione); ethane-1,2-diamine
SMILES
NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O

References

General References
  1. AIFA Product Information: Aminomal (aminophylline) for injection or rectal administration [Link]
Human Metabolome Database
HMDB0015354
KEGG Drug
D00227
PubChem Compound
9433
PubChem Substance
46508784
ChemSpider
9062
RxNav
689
ChEBI
2659
ChEMBL
CHEMBL1370561
Therapeutic Targets Database
DAP000613
PharmGKB
PA164781029
Drugs.com
Drugs.com Drug Page
Wikipedia
Aminophylline
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedPreventionAcute Kidney Injury (AKI)1
4CompletedPreventionPatients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson1
4CompletedTreatmentAnesthesia therapy1
4CompletedTreatmentPostdural Puncture Headache1
4Not Yet RecruitingTreatmentComplete Heart Block / Inferior Wall Myocardial Infarction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amend
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Dispensing Solutions
  • G & W Labs
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • PCA LLC
  • Pharmedix
  • Prescript Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage Forms
FormRouteStrength
SolutionIntravenous250 mg
SuppositoryRectal
Tablet, chewableOral
Injection, solutionIntravenous240 MG/10ML
Injection, solutionIntravenous; Parenteral240 MG/10ML
Injection, solutionIntravenous
Tablet, coatedOral
Injection, solution240 MG/10ML
Injection, solutionIntramuscular350 mg/2ml
Pill200 MG
SolutionIntramuscular350 mg/2ml
SuppositoryRectal350 MG
TabletOral600 mg
Tablet, extended releaseOral600 MG
InjectionIntravenous
InjectionIntravenous25 mg/1mL
Injection, solutionIntravenous25 mg/1mL
SolutionOral105 mg/5mL
TabletOral
TabletOral100 mg/1
TabletOral200 mg/1
Tablet, film coatedOral
SolutionIntravenous50 mg / mL
InjectionIntravenous0.25 g/10ml
SolutionIntravenous25 mg / mL
TabletOral100 mg / tab
TabletOral97.5 mg
InjectionIntravenous250 mg/10mL
SolutionParenteral250.000 mg
CapsuleOral200 mg
SolutionIntravenous240 mg
Tablet, extended releaseOral225 mg
Tablet, extended releaseOral350 mg
Injection, solutionIntramuscular
SuppositoryRectal250 mg/1
SuppositoryRectal500 mg/1
SolutionIntravenous250.000 mg
Solution25 mg/1ml
TabletOral100 mg
Tablet, coatedOral100 mg
Prices
Unit descriptionCostUnit
Aminophylline 250 mg/10 ml vial0.48USD ml
Aminophylline 25 mg/ml0.41USD ml
Phyllocontin-350 350 mg Sustained-Release Tablet0.31USD tablet
Aminophylline 100 mg tablet0.26USD tablet
Phyllocontin 225 mg Sustained-Release Tablet0.24USD tablet
Aminophylline powder0.17USD g
Aminophylline 200 mg tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility2E+005 mg/LMERCK INDEX (1996)
logP-3.03Not Available
Predicted Properties
PropertyValueSource
Water Solubility22.9 mg/mLALOGPS
logP-0.26ALOGPS
logP-0.77Chemaxon
logS-0.9ALOGPS
pKa (Strongest Acidic)7.82Chemaxon
pKa (Strongest Basic)-0.78Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area69.3 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity44.93 m3·mol-1Chemaxon
Polarizability16.86 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9778
Blood Brain Barrier+0.5908
Caco-2 permeable-0.6802
P-glycoprotein substrateSubstrate0.7341
P-glycoprotein inhibitor INon-inhibitor0.9164
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.7935
CYP450 2C9 substrateNon-substrate0.8073
CYP450 2D6 substrateNon-substrate0.8093
CYP450 3A4 substrateSubstrate0.5482
CYP450 1A2 substrateNon-inhibitor0.8726
CYP450 2C9 inhibitorNon-inhibitor0.9332
CYP450 2D6 inhibitorNon-inhibitor0.9633
CYP450 2C19 inhibitorNon-inhibitor0.9184
CYP450 3A4 inhibitorNon-inhibitor0.8031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8858
Ames testNon AMES toxic0.6724
CarcinogenicityNon-carcinogens0.8696
BiodegradationNot ready biodegradable0.9149
Rat acute toxicity2.4979 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7876
hERG inhibition (predictor II)Inhibitor0.6143
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-001i-1900000000-f6d60952fa154f363515
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-1900000000-f6d60952fa154f363515
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-182.76608
predicted
DeepCCS 1.0 (2019)
[M+H]+185.14821
predicted
DeepCCS 1.0 (2019)
[M+Na]+191.54904
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. cGMP-inhibited 3',5'-cyclic phosphodiesterase A
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
Gene Name
PDE3A
Uniprot ID
Q14432
Uniprot Name
cGMP-inhibited 3',5'-cyclic phosphodiesterase A
Molecular Weight
124978.06 Da
References
  1. Hirota K, Yoshioka H, Kabara S, Koizumi Y, Abe H, Sato T, Matsuki A: Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. [Article]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Details2. Adenosine receptor A1
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
References
  1. Yamamoto S, Nakanishi O, Matsui T, Shinohara N, Kinoshita H, Lambert C, Ishikawa T: Intrathecal adenosine A1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat. Cell Mol Neurobiol. 2003 Apr;23(2):175-85. [Article]
  2. Lerman BB: Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation. 1993 Feb;87(2):382-90. [Article]
Details3. Adenosine receptor A3
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled adenosine receptor activity
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.
Gene Name
ADORA3
Uniprot ID
P0DMS8
Uniprot Name
Adenosine receptor A3
Molecular Weight
36184.175 Da
References
  1. Stella L, de Novellis V, Marabese I, Berrino L, Maione S, Filippelli A, Rossi F: The role of A3 adenosine receptors in central regulation of arterial blood pressure. Br J Pharmacol. 1998 Oct;125(3):437-40. [Article]
Details4. Histone deacetylase 2
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Activator
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC2
Uniprot ID
Q92769
Uniprot Name
Histone deacetylase 2
Molecular Weight
55363.855 Da
References
  1. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. [Article]

Enzymes

Details1. Cytochrome P450 2E1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Tjia JF, Colbert J, Back DJ: Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7. [Article]
Details2. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Tjia JF, Colbert J, Back DJ: Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7. [Article]
Details3. Cytochrome P450 1A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT: Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48. [Article]
  2. CYP1A2, CTEP document, NIH [File]
  3. Cytochrome P450 Drug Interactions [File]

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55